Welcome to our dedicated page for Health In Tech SEC filings (Ticker: HIT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Health In Tech, Inc. filings document material-event disclosures for a Nevada operating company with Class A common stock listed on the Nasdaq Capital Market under HIT. Recent Form 8-K reports cover results of operations and financial condition, Regulation FD materials, investor presentations and conference-call transcripts.
The filing record also addresses capital-structure matters, including a private investment in public equity financing, and governance disclosures involving executive officer departures, compensatory arrangements and related consulting agreements. The company identifies as an emerging growth company in its Exchange Act reports.
Lockett Jonathan Del reported acquisition or exercise transactions in this Form 4 filing.
Health In Tech, Inc. Chief Strategy Officer Jonathan Del Lockett received a grant of 50,000 restricted shares of Class A Common Stock under the Health In Tech Equity Incentive Plan. These shares are subject to performance-based milestones and will be forfeited if those milestones are not achieved.
If the first milestone is met by on or before July 1, 2026, 20,000 shares will vest in equal monthly installments over 12 months. If a second milestone is met by on or before August 15, 2026, the remaining 30,000 shares will vest in equal monthly installments over 12 months. Following this award, he directly holds 143,539 shares, consisting of 78,985 unrestricted and 64,554 restricted shares, and also holds options to purchase 165,085 additional shares.
Health In Tech, Inc. is registering up to 5,600,000 shares of Class A Common Stock for resale by the selling stockholders.
This prospectus forms part of a shelf registration that permits the named selling stockholders to resell their Class A Common Stock from time to time; the company will not receive any proceeds from those resales. The Registration Rights Agreement arose from a PIPE Offering that closed on March 27, 2026.
Health In Tech, Inc. director and Chief Financial Officer Qian LinLin reported a tax-related share disposition. On May 14, 2026, she surrendered 23,324 shares of Class A Common Stock at $1.23 per share to the company to satisfy tax withholding obligations tied to vesting restricted stock.
After this transaction, she directly holds 9,083,751 Class A shares, including 1,060,738 restricted and 8,023,013 unrestricted shares. The filing notes this does not include 2,700,000 Class B shares or 711,510 stock options.
Health In Tech, Inc. Chief Executive Officer and 10% owner Tim Donald Johnson reported a tax-related share disposition. He surrendered 39,924 shares of Class A Common Stock at $1.23 per share to the company to satisfy tax withholding obligations tied to vesting restricted stock awards.
After this transaction, he directly holds 23,474,677 Class A shares, consisting of 1,037,478 restricted and 22,437,199 unrestricted Class A shares. This was a tax-withholding disposition rather than an open-market sale.
Health In Tech, Inc. Chief Growth Officer Hasan Zain Syed reported a compensation-related share disposition tied to tax withholding. On restricted stock vesting, he surrendered 4,205 shares of Class A Common Stock at $1.23 per share to cover tax obligations rather than selling them in the market.
After this transaction, Syed directly holds 212,347 Class A shares, including 205,680 restricted shares and 6,667 unrestricted shares. This filing reflects routine tax withholding associated with previously reported restricted stock awards.
Health In Tech, Inc. reports Q1 2026 results with total revenue of $8,771,646 and a net loss of $1,588,281, compared with net income in the prior-year quarter. Revenue grew mainly from fees, while underwriting modeling revenue declined.
Cost of revenues and operating expenses rose sharply, driven by higher sales and marketing, research and development, and amortization of capitalized software, compressing gross profit to $4,509,399. The company strengthened liquidity through a March 2026 PIPE, issuing 5,600,000 Class A shares at $1.25 per share for net proceeds of $6,381,000, lifting cash and cash equivalents to $10,325,208 at quarter end.
Health In Tech, Inc. reported first quarter 2026 revenue of $8.8 million, up about 9% year over year, as it shifts into an investment phase to support long-term growth. The company introduced new metrics to better explain its recurring business model and revenue visibility.
As of March 31, 2026, Contracted Revenue expected to be recognized over the remaining three quarters of 2026 was about $22.9 million, and first-quarter Platform Placed Plan Value reached $82 million in self-funded stop-loss plans placed through its platform. Management is reiterating full-year 2026 revenue guidance of $45–$50 million, implying roughly 35% to 50% growth.
Higher spending on sales, marketing, and product development drove an adjusted EBITDA loss of $1.3 million and a net loss of $1.6 million in the quarter. Operating expenses rose to $6.7 million, or 76% of revenue, as the company adds distribution capacity, enhances its AI-powered eDIYBS platform, and develops new offerings such as a Three-Year Rate Stabilization Program. A recent PIPE financing provided about $7 million in gross proceeds, leaving cash and equivalents at $10.3 million.
Health In Tech, Inc. presents an investor update highlighting its AI-powered marketplace that helps small and mid-sized employers access self-funded health plans paired with stop-loss insurance, while taking no plan or underwriting risk itself. The business earns recurring administrative fees and a share of stop-loss premiums.
Revenue grew from $19.5 million in 2024 to $33.3 million in 2025, with 2026 revenue guidance of $45–$50 million. First-quarter 2026 revenue rose to $8.8 million from $8.0 million, though Adjusted EBITDA shifted to a $(1.3) million loss as the company increases sales and marketing spending to drive future growth.
As of March 31, 2026, Health In Tech reported $10.3 million in cash and cash equivalents, $15.0 million in working capital and $21.6 million in stockholders’ equity. Business activity included $82.0 million of platform placed plan value, $22.9 million of contracted revenue for the remainder of 2026 and relationships with 896 brokers, third-party administrators and agencies.
Health In Tech, Inc. reported first quarter 2026 revenue of $8.8 million, up from $8.0 million a year earlier, driven mainly by higher fees revenue. The company posted a net loss of $1.6 million, compared with net income of $0.5 million in the prior-year quarter, as operating expenses rose sharply.
Adjusted EBITDA was a loss of $1.3 million versus positive $1.2 million a year ago. Management reiterated full-year 2026 revenue guidance of $45–$50 million, implying approximately 35% to 50% growth, supported by $22.9 million of contracted revenue as of March 31, 2026. A March 2026 private investment in public equity provided about $7.0 million in gross proceeds, lifting cash and cash equivalents to $10.3 million at quarter end.
Health In Tech, Inc. reported that Dustin Plantholt will depart from his role as Chief AI & Marketing Officer, effective April 30, 2026. The company states this change is part of a business transition and not due to any disagreement over operations, policies, or practices.
HITChain Inc., a subsidiary, entered into a Consulting Agreement dated May 1, 2026 with Plantholt Advisory Group LLC, owned and controlled by Mr. Plantholt. Under this arrangement, the consultant will receive monthly compensation and Mr. Plantholt will be granted 500,000 restricted shares of HITChain common stock, vesting in equal monthly installments over 12 months, subject to continued service. Either party may terminate the agreement with ten days’ prior written notice.